Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients
-
By
-
Hong-Thanh Nguyen
-
Minh-Duc Vu
-
Dinh-Dung Nguyen
-
Phuong-Nhung Dinh
-
Van-Quy Hoang
-
Linh-Trang Ngoc Bui
-
Dinh-Tuan Nguyen
-
Phuoc-Huy Do
-
Thi-Oanh Tong
-
Van-Hung Nguyen
-
Thu-Huong Thi Han
-
Sy-Tung Ha
-
Huy-Duong Do
-
Thanh-Ha Thi Ly
-
Viet-Nhan Nguyen
-
July 17, 2026
Clinical Scorecard: Characterization of BRCA1/2 Variants in Various Tumor Types of Vietnamese Patients Using Next-Generation Sequencing
At a Glance
| Category | Detail |
|---|
| Condition | BRCA1/2 mutations in hereditary cancers |
| Key Mechanisms | Disruption of DNA repair mechanisms leading to genomic instability and carcinogenesis. |
| Target Population | Vietnamese patients with breast, ovarian, prostate, and pancreatic cancers. |
| Care Setting | Oncology hospitals in Vietnam utilizing next-generation sequencing. |
Key Highlights
- BRCA1/2 mutations are significant risk factors for hereditary breast, ovarian, and prostate cancers.
- Next-generation sequencing is used to identify BRCA1/2 mutations in Vietnamese patients.
- PARP inhibitors show efficacy in treating BRCA-mutated cancers.
- Routine BRCA1/2 testing is recommended for personalized treatment strategies.
- There is a knowledge gap regarding BRCA1/2 mutation prevalence in the Vietnamese population.
Guideline-Based Recommendations
Diagnosis
- Follow NCCN Guidelines for Genetic/Familial High-Risk Assessment for breast, ovarian, pancreatic, and prostate cancers.
Management
- Consider PARP inhibitors for patients with BRCA-mutated cancers.
Monitoring & Follow-up
- Regularly assess BRCA1/2 mutation status in patients with relevant cancer types.
Risks
- Increased genomic instability and risk of carcinogenesis associated with BRCA1/2 mutations.
Patient & Prescribing Data
Patients diagnosed with triple-negative breast cancer, high-grade serous ovarian cancer, prostate cancer, or pancreatic cancer.
BRCA1/2 status is a key determinant in selecting targeted therapies.
Clinical Best Practices
- Implement routine BRCA1/2 testing for eligible cancer patients.
- Utilize next-generation sequencing for comprehensive mutation analysis.
- Provide genetic counseling based on BRCA1/2 testing results.
Related Resources & Content
